Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-negative, PR positive status confers therapeutic sensitivity to Everolimus, Exemestane in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.